Compare ROMA & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ROMA | RLMD |
|---|---|---|
| Founded | 2018 | 2004 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 503.9M | 524.9M |
| IPO Year | 2022 | 2012 |
| Metric | ROMA | RLMD |
|---|---|---|
| Price | $9.32 | $5.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $12.40 |
| AVG Volume (30 Days) | 13.7K | ★ 1.6M |
| Earning Date | 12-23-2025 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 45.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,070.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 154.83 |
| 52 Week Low | $1.16 | $0.55 |
| 52 Week High | $11.77 | $8.00 |
| Indicator | ROMA | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 51.61 | 35.69 |
| Support Level | $7.56 | $4.85 |
| Resistance Level | $9.75 | $7.28 |
| Average True Range (ATR) | 1.00 | 0.39 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 27.92 | 19.50 |
Roma Green Finance Ltd is principally engaged in the provision of ESG, corporate governance and risk management as well as sustainability and climate change-related advisory services. The company works closely with its clients to help them understand, identify, manage, and overcome various business matters arising from such factors related to ESG, sustainability and climate change. Geographically, the company generates its revenue from Hong Kong and Singapore.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.